Product Details
| Product Name:
Binodenoson |
CAS No.:
144348-08-3 |
| Purity:
99.84% |
Supply Ability:
10g |
| Release date:
2026/05/11 |
Product Introduction
Bioactivity
| Name | Binodenoson |
| Description | Binodenoson (WRC 0470) is a potent and selective A2A adenosine receptor agonist (KD=270 nM). Binodenoson is being developed as a short-acting coronary vasodilator as an adjunct to radiotracers for use in myocardial stress imaging[1]. |
| In vitro | 2-(cyclohexylmethylidenehydrazino)adenos (30-300 nM) decreases oxidative activity of tumor necrosis factor-α–primed FMLP-stimulated polymorphonuclear leukocytes in human whole blood and acts synergistically with Rolipram[1]. |
| In vivo | Binodenoson (infused 0-0.9 μg/kg/h; adult Wistar rat; rat bacterial meningitis model), with or without rolipram (0-0.01 μg/kg/h), inhibits pleocytosis and reduces the lipopolysaccharide-induced increase in blood-brain barrier permeability (BBBP), indicative of decreased neutrophil-induced damage[1]. |
| Storage | Keep away from direct sunlight,Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 11 mg/mL (28.1 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.11 mM), Sonication is recommended.
|
| Keywords | WRC-0470 | WRC0470 | stress | radiotracers | P1 receptor | oxidative | neutrophil | myocardial | MRE0470 | MRE 0470 | Inhibitor | inhibit | imaging | Binodenoson | AdenosineReceptor | Adenosine Receptor | A2A |
| Inhibitors Related | Xanthine | Theophylline monohydrate | Diphylline | Adenosine monophosphate | Acefylline | Sulcatone | Adenosine 5'-monophosphate monohydrate | Inosine | Theobromine | Adenosine 5'-monophosphate disodium salt | Theophylline | Doxofylline |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Nucleotide Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States